Search bioRxivSearch

Biology subjects

Schuck-Paim, C.

Publications and source records attributed to Schuck-Paim, C..

2 recordsLinked to original sources

Challenges in estimating the impact of vaccination with sparse data

BackgroundThe synthetic control (SC) model is a powerful tool to quantify the population-level impact of vaccines, because it can adjust for trends unrelated to vaccination using a composite of control diseases. Because vaccine impact studies are often conducted using smaller subnational datasets, we evaluated the performance of SC models with sparse time series data. To obtain more robust estimates of vaccine effects from noisy time series, we proposed a possible alternative approach, \"STL+PCA\" method (seasonal-trend decomposition plus principal component analysis), which first extracts smoothed trends from the control time series and uses them to adjust the outcome.\n\nMethodsUsing both the SC and STL+PCA models, we estimated the impact of 10-valent pneumococcal conjugate vaccine (PCV10) on pneumonia hospitalizations among cases <12 months and 80+ years of age during 2004-2014 at the subnational level in Brazil. The performance of these models was also compared using simulation analyses.\n\nResultsThe SC model was able to adjust for trends unrelated to PCV10 in larger states but not in smaller states. The simulation analysis confirmed that the SC model failed to select an appropriate set of control diseases when the time series were sparse and noisy, thereby generating biased estimates of the impact of vaccination when secular trends were present. The STL+PCA approach decreased bias in the estimates for smaller populations.\n\nConclusionsEstimates from the SC model might be biased when data are sparse. The STL+PCA model provides more accurate evaluations of vaccine impact in smaller populations.

epidemiology

Do pneumococcal conjugate vaccines (PCVs) reduce childhood pneumonia mortality? An assessment across socioeconomic groups in Brazil

BackgroundUnderstanding the real-world impact of pneumococcal conjugate vaccines (PCVs) on pneumonia mortality is critical, given the expectation that PCVs can substantially reduce the burden of pneumonia deaths in children under five years. However, surprisingly few post-vaccine introduction studies have estimated the benefit of PCVs for childhood mortality, and results have been inconsistent.\n\nMethodsWe investigated the long-term trends in child pneumonia mortality in Brazil (1980-present) and assessed the impact of PCV10 on childhood pneumonia mortality, both nationally and in municipalities stratified by socioeconomic status (SES), after the vaccine was introduced in Brazil in 2010.\n\nFindingsBetween 1980 and 2010, a period when Brazils Human Development Index (HDI) rose from 0.55 to 0.71, national pneumonia mortality in children under five decreased 10-fold. Despite rapid uptake of PCV10 following its introduction in 2010, our primary analytical method found no significant decline in national childhood pneumonia mortality, although a secondary analysis found a 10 percent decline in some but not all strata. However, at the municipal level we found significant reductions in childhood pneumonia mortality of up to 24% in low SES strata.\n\nInterpretationContrary to expectations, we found that PCV use led to at best modest savings in childhood pneumonia mortality at the national level in a middle-income country. In contrast, we found evidence that PCV led to larger reductions in low-income settings; a similar benefit might occur when PCVs are introduced in other low-SES settings. The long-term findings underscore that improvements in nutrition, hygiene, education, and healthcare play a major role in reducing pneumonia mortality.\n\nFundingThis work was funded by a grant from the Bill & Melinda Gates Foundation (OPP1114733). DMW also acknowledges support from the Bill and Melinda Gates Foundation (OPP1176267) and the National Institute of Allergy and Infectious Diseases (R01AI123208)

epidemiology